Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319461936> ?p ?o ?g. }
- W4319461936 abstract "Background The current standard of care for the treatment of patients with primary mitral regurgitation (MR) is surgical mitral valve repair. Transcatheter edge-to-edge repair with the MitraClip device provides a less invasive treatment option for patients with both primary and secondary MR. Worldwide, >150 000 patients have been treated with the MitraClip device. However, in the United States, MitraClip is approved for use only in primary patients with MR who are at high or prohibitive risk for mitral valve surgery. The REPAIR MR (Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery) trial is designed to compare early and late outcomes associated with transcatheter edge-to-edge repair with the MitraClip and surgical repair of primary MR in older or moderate surgical risk patients. Methods and Results The REPAIR MR trial is a prospective, randomized, parallel-controlled, open-label multicenter, noninferiority trial for the treatment of severe primary MR (verified by an independent echocardiographic core laboratory). Patients with severe MR and indications for surgery because of symptoms (New York Heart Association class II-IV), or without symptoms with left ventricular ejection fraction ≤60%, pulmonary artery systolic pressure >50 mm Hg, or left ventricular end-systolic diameter ≥40 mm are eligible for the trial provided they meet the moderate surgical risk criteria as follows: (1) ≥75 years of age, or (2) if <75 years of age, then the subject has a Society of Thoracic Surgeons Predicted Risk Of Mortality score of ≥2% for mitral repair (or Society of Thoracic Surgeons replacement score of ≥4%), or the presence of a comorbidity that may introduce a surgery-specific risk. The local surgeon must determine that the mitral valve can be surgically repaired. Additionally, an independent eligibility committee will confirm that the MR can be reduced to mild or less with both the MitraClip and surgical mitral valve repair with a high degree of certainty. A total of 500 eligible subjects will be randomized in a 1:1 ratio to receive the MitraClip device or to undergo surgical mitral valve repair (control group). There are 2 co-primary end points for the trial, both of which will be evaluated at 2 years. Each subject will be followed for 10 years after enrollment. The study has received approval from both the Food and Drug Administration and the Centers for Medicare and Medicaid Services, and enrolled its first subject in July 2020. Conclusions The REPAIR MR trial will determine the safety and effectiveness of transcatheter edge-to-edge repair with the MitraClip in patients with primary MR who are at moderate surgical risk and are candidates for surgical MV repair. The trial will generate contemporary comparative clinical evidence for the MitraClip device and surgical MV repair. Registration https://clinicaltrials.gov/ct2/show/NCT04198870; NCT04198870." @default.
- W4319461936 created "2023-02-09" @default.
- W4319461936 creator A5002939213 @default.
- W4319461936 creator A5007024868 @default.
- W4319461936 creator A5022830903 @default.
- W4319461936 creator A5025651975 @default.
- W4319461936 creator A5029829293 @default.
- W4319461936 creator A5032182838 @default.
- W4319461936 creator A5034367622 @default.
- W4319461936 creator A5058664452 @default.
- W4319461936 creator A5060149925 @default.
- W4319461936 creator A5060436966 @default.
- W4319461936 creator A5061706688 @default.
- W4319461936 creator A5068594160 @default.
- W4319461936 creator A5079113475 @default.
- W4319461936 creator A5079749832 @default.
- W4319461936 creator A5081695585 @default.
- W4319461936 creator A5084185852 @default.
- W4319461936 date "2023-02-21" @default.
- W4319461936 modified "2023-10-03" @default.
- W4319461936 title "Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery: Design and Rationale of the REPAIR MR Trial" @default.
- W4319461936 cites W1582492844 @default.
- W4319461936 cites W1963916270 @default.
- W4319461936 cites W1991574984 @default.
- W4319461936 cites W2011621467 @default.
- W4319461936 cites W2017936383 @default.
- W4319461936 cites W2078826716 @default.
- W4319461936 cites W2086712839 @default.
- W4319461936 cites W2106089315 @default.
- W4319461936 cites W2106118893 @default.
- W4319461936 cites W2106155862 @default.
- W4319461936 cites W2122694177 @default.
- W4319461936 cites W2191399290 @default.
- W4319461936 cites W2253321630 @default.
- W4319461936 cites W2735818196 @default.
- W4319461936 cites W2751630023 @default.
- W4319461936 cites W2789349441 @default.
- W4319461936 cites W2883876578 @default.
- W4319461936 cites W2898483670 @default.
- W4319461936 cites W2942352388 @default.
- W4319461936 cites W2969451766 @default.
- W4319461936 cites W2970397770 @default.
- W4319461936 cites W2976378563 @default.
- W4319461936 cites W2980538879 @default.
- W4319461936 cites W3002039074 @default.
- W4319461936 cites W3038634625 @default.
- W4319461936 cites W3091646497 @default.
- W4319461936 cites W3091916999 @default.
- W4319461936 cites W3110253424 @default.
- W4319461936 cites W3112785303 @default.
- W4319461936 cites W3130459987 @default.
- W4319461936 cites W3158898376 @default.
- W4319461936 cites W3161524032 @default.
- W4319461936 cites W3210887269 @default.
- W4319461936 cites W2980676406 @default.
- W4319461936 doi "https://doi.org/10.1161/jaha.122.027504" @default.
- W4319461936 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36752231" @default.
- W4319461936 hasPublicationYear "2023" @default.
- W4319461936 type Work @default.
- W4319461936 citedByCount "4" @default.
- W4319461936 countsByYear W43194619362023 @default.
- W4319461936 crossrefType "journal-article" @default.
- W4319461936 hasAuthorship W4319461936A5002939213 @default.
- W4319461936 hasAuthorship W4319461936A5007024868 @default.
- W4319461936 hasAuthorship W4319461936A5022830903 @default.
- W4319461936 hasAuthorship W4319461936A5025651975 @default.
- W4319461936 hasAuthorship W4319461936A5029829293 @default.
- W4319461936 hasAuthorship W4319461936A5032182838 @default.
- W4319461936 hasAuthorship W4319461936A5034367622 @default.
- W4319461936 hasAuthorship W4319461936A5058664452 @default.
- W4319461936 hasAuthorship W4319461936A5060149925 @default.
- W4319461936 hasAuthorship W4319461936A5060436966 @default.
- W4319461936 hasAuthorship W4319461936A5061706688 @default.
- W4319461936 hasAuthorship W4319461936A5068594160 @default.
- W4319461936 hasAuthorship W4319461936A5079113475 @default.
- W4319461936 hasAuthorship W4319461936A5079749832 @default.
- W4319461936 hasAuthorship W4319461936A5081695585 @default.
- W4319461936 hasAuthorship W4319461936A5084185852 @default.
- W4319461936 hasBestOaLocation W43194619361 @default.
- W4319461936 hasConcept C126322002 @default.
- W4319461936 hasConcept C141071460 @default.
- W4319461936 hasConcept C164705383 @default.
- W4319461936 hasConcept C168563851 @default.
- W4319461936 hasConcept C2777543888 @default.
- W4319461936 hasConcept C2778198053 @default.
- W4319461936 hasConcept C2780679668 @default.
- W4319461936 hasConcept C2780793704 @default.
- W4319461936 hasConcept C2780813298 @default.
- W4319461936 hasConcept C2993373945 @default.
- W4319461936 hasConcept C71924100 @default.
- W4319461936 hasConcept C78085059 @default.
- W4319461936 hasConceptScore W4319461936C126322002 @default.
- W4319461936 hasConceptScore W4319461936C141071460 @default.
- W4319461936 hasConceptScore W4319461936C164705383 @default.
- W4319461936 hasConceptScore W4319461936C168563851 @default.
- W4319461936 hasConceptScore W4319461936C2777543888 @default.
- W4319461936 hasConceptScore W4319461936C2778198053 @default.
- W4319461936 hasConceptScore W4319461936C2780679668 @default.
- W4319461936 hasConceptScore W4319461936C2780793704 @default.
- W4319461936 hasConceptScore W4319461936C2780813298 @default.